Verve Therapeutics Inc

NASDAQ:VERV  
32.57
-0.61 (-1.84%)
Other Pre-Announcement

Verve Therapeutics Announces 2022 Anticipated Milestones And Preclinical Data On Potential Additional Dosing Regimens For Its Novel Base Editing Programs

Published: 01/10/2022 11:41 GMT
Verve Therapeutics Inc (VERV) - Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for Its Novel Base Editing Programs.
Verve Therapeutics Inc - Verve-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022.
Verve Therapeutics Inc - Angptl3 Program Initiation of Ind-enabling Studies Expected in Second Half of 2022.